About: Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers
Creator	Williams, J Du, S Gerdemann, U Hodgson, C Leen, A Luke, J Vincent, J Whalen, R
Source	Medline; PMC
abstract	Methods to improve plasmid-mediated transgene expression are needed for gene medicine and gene vaccination applications. To maintain a low risk of insertional mutagenesis-mediated gene activation, expression-augmenting sequences would ideally function to improve transgene expression from transiently transfected intact plasmid, but not from spurious genomically integrated vectors. We report herein the development of potent minimal, antibiotic-free, high-manufacturing-yield mammalian expression vectors incorporating rationally designed additive combinations of expression enhancers. The SV40 72 bp enhancer incorporated upstream of the cytomegalovirus (CMV) enhancer selectively improved extrachromosomal transgene expression. The human T-lymphotropic virus type I (HTLV-I) R region, incorporated downstream of the CMV promoter, dramatically increased mRNA translation efficiency, but not overall mRNA levels, after transient transfection. A similar mRNA translation efficiency increase was observed with plasmid vectors incorporating and expressing the protein kinase R-inhibiting adenoviral viral associated (VA)1 RNA. Strikingly, HTLV-I R and VA1 did not increase transgene expression or mRNA translation efficiency from plasmid DNA after genomic integration. The vector platform, when combined with electroporation delivery, further increased transgene expression and improved HIV-1 gp120 DNA vaccine-induced neutralizing antibody titers in rabbits. These antibiotic-free vectors incorporating transient expression enhancers are safer, more potent alternatives to improve transgene expression for DNA therapy or vaccination. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/gt.2010.149) contains supplementary material, which is available to authorized users.
has issue date	2010-11-25(xsd:dateTime)
bibo:doi	10.1038/gt.2010.149
bibo:pmid	21107439
has license	no-cc
sha1sum (hex)	fe6877441782523d1483c16be6c6c1886b2dbfeb
schema:url	https://doi.org/10.1038/gt.2010.149
resource representing a document's title	Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers
has PubMed Central identifier	PMC7091570
has PubMed identifier	21107439
schema:publication	Gene Ther
resource representing a document's body	covid:fe6877441782523d1483c16be6c6c1886b2dbfeb#body_text
is schema:about of	named entity 'gene' named entity 'transgene' named entity 'type I' named entity 'enhancers' named entity 'efficiency' named entity 'combinations' named entity 'These' named entity 'CMV promoter' named entity 'HTLV-I' named entity 'AUGMENTING' named entity 'VIRUS TYPE' named entity 'VACCINATION' named entity 'INTEGRATION' named entity 'MAMMALIAN' named entity 'ASSOCIATED' named entity 'INSERTIONAL MUTAGENESIS' named entity 'MRNA TRANSLATION' named entity 'EXPRESSION VECTORS' named entity 'INTACT' named entity 'INHIBITING' named entity 'BUT' named entity 'CYTOMEGALOVIRUS' named entity 'GP120' named entity 'TYPE I' named entity 'LEVELS' named entity 'HIV-1' named entity 'LOW RISK' named entity 'HTLV-I' named entity 'MRNA' named entity 'RABBITS' named entity 'DNA VACCINE' named entity 'HIGH' named entity 'TRANSGENE EXPRESSION' named entity 'NEEDED' named entity 'MANUFACTURING' named entity 'UPSTREAM' named entity 'FUNCTION' named entity 'MEDIATED' named entity 'CMV PROMOTER' named entity 'COMBINED' named entity 'OVERALL' named entity 'ADENOVIRAL' named entity 'MINIMAL' named entity 'PLASMID VECTORS' named entity 'GENOMIC' named entity 'INCREASED' named entity 'ANTIBIOTIC' named entity 'FREE' named entity 'GENE ACTIVATION' named entity 'COMBINATIONS' named entity 'APPLICATIONS' named entity 'PLATFORM' named entity 'RNA' named entity 'EFFICIENCY' named entity 'PLASMID' named entity 'SV40' named entity 'INCREASE' named entity 'TRANSIENT EXPRESSION' named entity 'NEUTRALIZING ANTIBODY' named entity 'PROTEIN KINASE R' named entity 'DID' named entity 'PLASMID DNA' named entity 'ENHANCERS' named entity 'DESIGN' named entity 'SEQUENCES' named entity 'EXPRESSION' named entity 'INTEGRATED' named entity 'DNA THERAPY' named entity 'TRANSIENT TRANSFECTION' named entity 'YIELD' named entity 'VECTORS' named entity 'ELECTROPORATION' named entity 'PLASMID VECTOR' named entity 'IMPROVED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software